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Background:We searched for novel regulators of insulin-stimulated glucose transport in adipocytes.
Results: Tumor suppressor candidate 5 (TUSC5) colocalized with GLUT4, and manipulation of TUSC5 expression levels
affected insulin-regulated glucose transport.
Conclusion: TUSC5 is a novel regulator of insulin-stimulated glucose transport.
Significance: TUSC5 contributes to insulin-sensitizing effects of PPAR agonists in adipocytes.
Insulin signaling augments glucose transport by regulating
glucose transporter 4 (GLUT4) trafficking from specialized
intracellular compartments, termed GLUT4 storage vesicles
(GSVs), to theplasmamembrane. Proteomic analysis ofGSVsby
mass spectrometry revealed enrichment of 59 proteins in these
vesicles. We measured reduced abundance of 23 of these pro-
teins following insulin stimulation and assigned these as high
confidence GSV proteins. These included established GSV pro-
teins such as GLUT4 and insulin-responsive aminopeptidase, as
well as six proteins not previously reported to be localized to
GSVs. Tumor suppressor candidate 5 (TUSC5) was shown to be
a novel GSV protein that underwent a 3.7-fold increase in abun-
dance at the plasma membrane in response to insulin.
siRNA-mediated knockdown of TUSC5 decreased insulin-stim-
ulated glucose uptake, although overexpression of TUSC5 had
the opposite effect, implicating TUSC5 as a positive regulator of
insulin-stimulated glucose transport in adipocytes. Incubation
of adipocytes with TNF caused insulin resistance and a con-
comitant reduction inTUSC5.Consistentwith previous studies,
peroxisome proliferator-activated receptor (PPAR)  agonism
reversed TNF-induced insulin resistance. TUSC5 expression
was necessary but insufficient for PPAR-mediated reversal of
insulin resistance. These findings functionally link TUSC5 to
GLUT4 trafficking, insulin action, insulin resistance, and
PPAR action in the adipocyte. Further studies are required to
establish the exact role of TUSC5 in adipocytes.
Insulin regulates blood glucose levels in part by stimulating
the translocation ofGLUT4 froman intracellular compartment
to the plasmamembrane (PM)6 of adipocytes andmyocytes (1).
This process is defective in insulin resistance (2).
In the absence of insulin, GLUT4 resides within specialized
insulin-sensitive 50–70-nm storage vesicles (3, 4), termed
GLUT4-storage vesicles (GSVs). These vesicles are distinct
from the general endosomal recycling pathway, effectively
sequestering GLUT4 andmaintaining low levels of PMGLUT4
in the absence of insulin. Insulin signals via the canonical phos-
phatidylinositol 3-kinase (PI3K)/AKT signaling pathway to
trigger the release, translocation, docking, and fusion of GSVs
with the PM (5, 6). Mobilization of GSVs to the PM upon insu-
lin stimulation permits a large augmentation of cell surface
GLUT4 levels and thus glucose transport into the cell. Activa-
tion of AKT is necessary and sufficient for GSV exocytosis (5),
and this is thought to be primarily mediated through AKT-de-
pendent phosphorylation and inactivation of the TBC1D4/
AKT substrate of 160 kDa (AS160), a RAB-GAP residing on
GSVs (5, 7–9). The identification of TBC1D4 as an AKT sub-
strate and GSV-associated protein represents a major advance
in our understanding of the intersection between insulin signal-
ing and GLUT4 traffic. In addition to TBC1D4, established
GSV resident proteins have been reported to regulate GLUT4
traffic in different ways as follows: those proteins that regulate
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GSV formation (e.g. sortilin (10)); those that regulate GSV traf-
ficking either as part of the signaling response or by directing
membrane traffic (e.g. TBC1D4 (9), RAB10 (11–13), and
VAMP2 (14)); and those that are delivered to the PM as cargo
within GSVs (e.g. GLUT4, insulin-responsive aminopeptidase
(IRAP) (15), and low density lipoprotein receptor-related pro-
tein 1 (LRP1) (16)).
Insulin-regulated GLUT4 trafficking in adipocytes is defec-
tive in insulin-resistant conditions. PPAR agonists, such as the
thiazolidinediones (e.g. rosiglitazone), enhance whole body
insulin sensitivity (17–19) and restore insulin-regulated glu-
cose transport in insulin-resistant adipocytes (20–24). Further-
more, PPAR activation in adipose tissue alone has been
reported to be sufficient for whole body insulin sensitization
(23). It has been proposed that the insulin sensitizing activity of
PPAR activation may be mediated via a range of pathways,
including the following: enhanced adipocyte differentiation
(25, 26); altered expression of key intermediates such asGLUT4
(20, 24, 27–29), IRS1, IRS2, PI3K P85 (23), and PTEN (30);
reduced production of inflammatory cytokines (31); altered
GLUT4 recycling (22); reduced oxidative stress (21); increased
mitochondrial biogenesis (32); and inhibition of mitochondrial
respiration (33). Interestingly, no individual PPAR target
genes, other than GLUT4 itself, have been found to participate
directly in GSV trafficking.
Given the importance of the GSV compartment to the insu-
lin response, and recent advances in the sensitivity of mass
spectrometry instruments, we sought to expand the repertoire
of known GSV proteins and to identify novel regulators of
GLUT4 traffic by targeting GSVs for proteomic analysis (9, 16).
Our analysis revealed a number of novel GSV proteins, which
likely denote novel regulatory features of GSVs. One such pro-
tein, tumor suppressor candidate 5 (TUSC5), was rapidlymobi-
lized to the cell surface following insulin stimulation. Genetic
manipulation of Tusc5 expression placed TUSC5 as a positive
regulator of insulin-stimulated glucose transport. Further-
more, we provide evidence that enhanced TUSC5 expression
forms part of the insulin-sensitizing action of the PPAR ago-
nist rosiglitazone. Our findings implicate TUSC5 as a novel
regulator of insulin action in adipocytes.
Experimental Procedures
Immunoisolation of GSVs from Primary Rat Adipocytes—
Adipose cells from epididymal fat pads of male Wistar rats
weighing 180–200 g were prepared by collagenase digestion as
described previously (34). Adipocytes at 40% cytocrit were
stimulatedwith 20 nM insulin for 20min at 37 °C. The cells were
homogenized in HES buffer (20 mM HEPES, pH 7.0, 0.5 mM
EGTA, 250mMsucrose) supplementedwith protease inhibitors
andprocessed as described previously (35) to obtain a post-high
density microsome supernatant (pHS) or low density micro-
somes (LDM). GLUT4 vesicles were purified by immunoisola-
tion using an anti-GLUT4 antibody (36) prebound to the malt-
ose-binding protein-protein A construct attached to amylose
resin (New England Biolabs) as described previously (37). After
a 2-h incubation, the column was washed with HES buffer, and
the GLUT4 vesicles were eluted in 40 mM maltose, 100 mM
Tris-HCl, pH 7.4, and protease inhibitors. The eluted fractions
were concentrated with Amicon ultra spin filters (Millipore
10,000 molecular weight cutoff) to reduce the elution volume,
and SDS was added to 2% w/v final concentration.
Immunoisolation of GSVs from 3T3-L1 Adipocytes—3T3-L1
adipocytes were serum-starved in basal DMEM (DMEM,
GlutaMAX, and 0.2% bovine serum albumin (BSA)) for 2 h
prior to 100 nM insulin stimulation for 20 min where indicated.
Cells were washed with ice-cold PBS and harvested in ice-cold
HES-I buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 250 mM
sucrose containing Complete protease inhibitor mixture
(Roche Applied Science)). All subsequent steps were carried
out at 4 °C. Cells were homogenized by passing through 22- and
27-gauge needles prior to centrifugation at 500 g for 10 min.
The supernatant was centrifuged at 13,550  g for 12 min to
yield a pellet (PM/mitochondria/nuclei) and a supernatant
fraction consisting of cytosol, LDM, and high density micro-
somes (HDM). The supernatant was then centrifuged at
21,170 g for 17 min to obtain the HDM pellet and the super-
natant containing the LDM and cytosol fractions (herein
referred to as the post-HDM supernatant, pHS). Protein con-
centration of pHS was determined using BCA assay (Thermo
Scientific). Equal amounts of protein from each pHS was incu-
bated with protein G-agarose beads (GE Healthcare) conju-
gated either to anti-GLUT4 (1F8 monoclonal anti-mouse anti-
body) or IgG control antibody (Sigma) for 2 h with rotation.
Beads were washed three times with HES-I, followed by two
washes with PBS, and precipitated proteins were eluted in 2
SDS-PAGE loading buffer (65.8 mM Tris-HCl, pH 6.8, 2.1%
SDS, 26.3% (v/v) glycerol, 0.01% bromphenol blue) containing
20 mM DTT.
Protein Fractionation by SDS-PAGE forMass Spectrometry—
Immunoisolated proteins were reduced with 10 mM DTT for
1 h at room temperature and alkylated with 25 mM iodoacet-
amide for 30 min in the dark before iodoacetamide was
quenched with 10 mM DTT. Samples were diluted in NuPAGE
LDS sample buffer (141 mM Tris base, 2% lithium dodecyl sul-
fate, 10% glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue G,
0.175 mM phenol red) (Life Technologies, Inc.) prior to SDS-
PAGE. Samples were run on an 8–12% bis/acrylamide SDS-
PAGE Precast NuPAGE gel (Life Technologies, Inc.). Gels were
stained with Sypro Ruby protein gel stain (Life Technologies,
Inc.) according to the manufacturer’s instructions and imaged
on a Fujifilm FLA-5100 (Fujifilm).
In-gel Digestion—Each lanewas cut into 10 separate fractions
for in-gel digestion. Gel fractions were washed in 50% acetoni-
trile (MeCN, Thermo Scientific) in 50 mM triethylammonium
bicarbonate (TEAB, Sigma) at room temperature for 15 min,
vortexing occasionally. Gel pieces were dehydrated in 100%
MeCN at room temperature for 5min and rehydrated in 50mM
TEAB at room temperature for 5 min. This dehydration/rehy-
dration procedurewas repeated butwith the rehydration buffer
containing 10 ng/l trypsin (Promega) in 50 mM TEAB. Digest
was carried out overnight at 37 °C. Peptides were solubilized by
the addition of formic acid (Thermo Scientific) to 5% and incu-
bation at 37 °C for 30 min. To extract peptides, gel pieces were
dehydrated using 100% MeCN and incubated at 37 °C for 15
min. Peptideswere transferred to a new tube anddried and then
resuspended and acidified in 1% v/v trifluoroacetic acid (TFA,
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Thermo Scientific). Resuspended peptides were centrifuged for
at 21,000 g for 10min at 4 °C. Each sample was desalted using
C18 membranes (3 M) as described previously (38).
Nano-reverse Phase Liquid Chromatography-Electrospray
Ionization-Tandem Mass Spectrometry—Peptides were resus-
pended in 0.5% acetic acid and separated by reverse phase liquid
chromatography on an in-house packed 17-cm  75-m
Reprosil-Pur C18-AQ column (1.9 m, Dr. Maisch) using an
EASY nLC-II nanoHPLC (Proxeon). The HPLC gradient was
0–40% solvent B (solvent A, 0.5% acetic acid; solvent B, 90%
acetonitrile, 0.5% acetic acid) over 90 min at a flow of 250
nl/min. MS was performed using an LTQ-Orbitrap Velos Pro
(Thermo Scientific). AnMS scan (300–1750m/z; MSAGC 3
106) was recorded in theOrbitrap set at a resolution of 60,000 at
400m/z followed by data-dependent collision-induced dissoci-
ation MS/MS of the 20 most intense precursor ions. An MS
scan (300–1750 m/z; automatic gain control 3  106) was
recorded in theOrbitrap set at a resolution of 60,000 at 400m/z
followed by data-dependent collision-induced dissociation
MS/MS of the 20 most intense precursor ions. Parameters for
collision-induced dissociation were as follows: normalized
energy 35, dynamic duration 60 s, maximum injection time 150
ms, and tandemMS automatic gain control 4 105.
Mass Spectrometric Data Analysis—Raw mass spectrometry
data were processed using theMaxQuant software (39) version
1.2.3.3 using the default settings withminor changes as follows:
oxidized methionine (Met), acetylation (N-terminal protein)
were selected as variable modifications and carbamidomethyl
as fixedmodification. Amaximum of twomissed cleavages was
permitted, 10 peaks per 100 Da, MS/MS tolerance of 20 ppm,
and a minimum peptide length of 7. The “matching between
runs” algorithmwas enabled (timewindow 2min) to transfer
identifications between adjacent fractions. Database searching
was performed using the Andromeda search engine integrated
into the MaxQuant environment (40) against the rat Uniprot
database (October, 2013). Protein, peptide, and site false dis-
covery rate thresholds in MaxQuant were each set to a maxi-
mum of 1%. Relative protein abundances were estimated using
the “Label-free Quantification Method” (LFQ) algorithm (41)
within the MaxQuant environment. Resulting “LFQ” intensi-
ties were used for analysis.
Analyses of mass spectrometry data were performed in R
programming environment (42). All data were log2-trans-
formed and normalized using the median absolute deviation
(43) method. Missing values in IgG control and insulin-stimu-
lated samples of each experiment were imputed 20 times and
averaged. Imputation was performed by generating a Gaussian
distribution with mean () set to the minimum value for each
condition, and the standard deviation () was the  of the 1st
quartile of the distribution for each condition. Normally dis-
tributed random variables from this minimum value distribu-
tion were used to replace the missing values.
Statistical Analysis—Only proteins identified in all replicates
(n 2 for LDM and n 2 for pHS) were retained for statistical
analysis. The top 5% most variable data (determined by stan-
dard deviation) were removed prior to analysis. We filtered for
high confidence GSV-resident proteins by selecting proteins
with features similar to a positive control set (GLUT4, IRAP,
VAMP2, and sortilin). These features were enrichment of pro-
teinswithinGSVs andLFQ intensity as ameasure of abundance
and insulin responsiveness. For analysis of both enrichment
(basal versus IgG) and insulin responsiveness (Insulin versus
basal), the significance of each protein was calculated using a
moderated t test from LIMMA package (44). Test statistics (t
statistics) were obtained separately for each immunoisolation
method (LDM or pHS) and converted to Z-scores. An inte-
grated p value was derived by testing for proteins that were
altered in both LDM and pHS in the positive quadrant for
enriched proteins using directPA package (45). Only proteins
with LFQ intensities greater than the population median were
considered for further analysis. An integrated p value was also
derived for the insulin responsiveness of proteins using the
same method, by testing for proteins altered in both LDM and
pHS in the negative quadrant.
Nonlinear regressions to calculate ED50 values, linear regres-
sions to determine r2 values, t tests, and ANOVAs were per-
formed using GraphPad Prism version 6.00 for Windows
(GraphPad software). Specific statistical tests are specified in
figure legends.
Cloning of TUSC5—TheTusc5 genewas cloned from 3T3-L1
cDNA into pcDNA3.1 and subsequently into pBABE-puro,
using Gibson assembly cloning (46). The sequences of cloning
primers are available upon request. Constructs were confirmed
by sequencing.
Cell Culture—3T3-L1 fibroblasts were passaged at 60%
confluency in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum (FBS), GlutaMAX (Life
Technologies, Inc.) at 37 °C with 10% CO2. Differentiation was
induced at 100% confluence by addition of 350 nM insulin, 0.5
mM 3-isobutyl-1-methylxanthine, 250 nM dexamethasone, and
400 nM biotin for 3 days. Cells were then incubated in the pres-
ence of 350 nM insulin for 3 days. Adipocytes were used
between days 10 and 12 after initiation of differentiation. For
overexpression of TUSC5 and/or hemagglutinin (HA)-tagged-
GLUT4 3T3-L1, fibroblasts were infected with pBABE puro
retrovirus (empty vector control) and pBabepuro-TUSC5 ret-
rovirus alone or in combination with pWZLneo HA-GLUT4
retrovirus. Puromycin (2 g/ml) was used for selection of cells
infected with pBABE puro retrovirus. Cells were also selected
with geneticin (800 g/ml) if infected with pWZLneo HA-
GLUT4 retrovirus. For induction of insulin resistance by
TNF, adipocytes were incubated with 2 ng/ml TNF for 96 h.
Rosiglitazone (10 M) treatments were carried out during the
final 48 h of TNF treatment.
Subcellular Fractionation—3T3-L1 adipocytes were serum-
starved in basal DMEM for 2 h prior to stimulation with 100 nM
insulin for 20 min before being subjected to subcellular frac-
tionation.Cellswerewashedwith ice-cold PBS andharvested in
ice-cold HES-I buffer. All subsequent steps were carried out at
4 °C. Cells were homogenized by passing through 22- and
27-gauge needles prior to centrifugation at 500 g for 10 min.
The supernatant was centrifuged at 13,550  g for 12 min to
pellet the PM and mitochondria/nuclei, and the supernatant
fraction consisted of cytosol, LDM, andHDM.The supernatant
was then centrifuged at 21,170 g for 17min to pellet theHDM
fraction. The supernatant was again centrifuged at 235,200 g
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for 75 min to obtain the cytosol fraction (supernatant) and the
LDM fraction (pellet). The PM and mitochondria/nuclei pellet
were resuspended inHES-I and centrifuged at 13,550 g for 12
min. ThePMandmitochondria/nuclei pelletwere resuspended
in HES-I and layered over a high sucrose HES-I buffer (1.12 M
sucrose, 0.05 mM EDTA, 10 mM HEPES, pH 7.4) and centri-
fuged at 111,160  g for 60 min in a swing-out rotor. The PM
fraction was collected above the sucrose layer, and the pellet
was the mitochondria/nuclei fraction. All the fractions were
resuspended in HES-I. Protein concentration for each fraction
was performed using BCA assay (Thermo Scientific).
Mouse Tissue Lysate Production—Tissues were isolated from
themouse and homogenized inHES-SDS (2% (w/v) SDS)with a
Dounce homogenizer followed by sonication. Samples were
centrifuged at 13,000 g for 10 min at room temperature. The
supernatant was collected, and protein concentration was
determined by BCA assay (Thermo Scientific).
Immunofluorescence Confocal Microscopy—3T3-L1 adipo-
cytes were seeded onto Matrigel matrix-coated 8-well micro-
slides (Ibidi). Cells were serum-starved in basal DMEMat 37 °C
before stimulation with 100 nM insulin for 20 min. Cells were
washed in ice-cold PBS, fixed with 3.8% paraformaldehyde, and
quenched with 50 mM glycine. Cells were then blocked and
permeabilized in 2% BSA and 0.1% saponin in PBS and incu-
bated with anti-GLUT4 (1F8, mouse), anti-TUSC5 (rabbit,
Santa Cruz Biotechnology), and anti-EEA1 (Dr. Marvin Frit-
zler, University of Calgary). Primary antibodies were detected
with anti-mouse Alexa-488-conjugated secondary, anti-rabbit
Alexa-555-conjugated secondary antibody, and anti-human
Alexa-647-conjugated secondary antibody. 4,6-Diamidino-2-
phenylindole, dihydrochloride (DAPI), was used to visualize
nuclei (Life Technologies, Inc.). The imaging medium was
2.5% 1,4-diazabicyclo[2.2.2]octane, 5% glycerol in PBS. Opti-
cal sections were obtained using the Leica TCS SP8 confocal
laser scanning microscope using a HC PL APO 63/1.20 W
CORR CS2 objective and HyD detectors at 22 °C. Images were
acquired using Leica LCS software. All images were processed
using Fiji (47).
Total Internal Reflection Fluorescence (TIRF) Microscopy—
3T3-L1 adipocytes or 3T3-L1 adipocytes expressing HA-
GLUT4 were seeded onto Matrigel matrix-coated 8-well
microslides (Ibidi), serum-starved, and treated with insulin as
above. Cells were washed in ice-cold PBS, fixed with 3.8% para-
formaldehyde, and quenched with 50 mM glycine. For assess-
ment of only plasma membrane HA-GLUT4 and TUSC5, cells
were blocked in 2% BSA in PBS and incubated with anti-HA
(Covance, mouse) and anti-TUSC5 (rabbit, Santa Cruz Bio-
technology). Primary antibodies were detected with anti-
mouse Alexa-488-conjugated secondary and anti-rabbit Alexa-
555-conjugated secondary antibodies. For visualization of
endogenous GLUT4 and TUSC5 by TIRF, cells were blocked
and permeabilized in 2% BSA and 0.1% saponin in PBS and
incubated with anti-GLUT4 (1F8, mouse) and anti-TUSC5
(rabbit, Santa Cruz Biotechnology). Primary antibodies were
detected with anti-mouse Alexa-488-conjugated secondary
antibody and anti-rabbitAlexa-555-conjugated secondary anti-
body. DAPI was used to visualize nuclei (Life Technologies,
Inc.). The imaging medium was 2.5% 1,4-diazabicyclo-
[2.2.2]octane, 5% glycerol in PBS. Images were acquired on a
Nikon Ti-E microscope at 25 °C. Total internal reflection fluo-
rescence microscopy was performed using 488- and 555-nm
lasers introduced into the excitation light path through the
LApps H-TIRF module (Nikon) angled to image110 nm into
cells. Fluorescence was detected using an Andor iXon3 888
EMCCD camera. Data analysis was performed using a combi-
nation of Fiji (47), ilastik (48), and Cell Profiler (49).
siRNA-mediated Tusc5 Knockdown—7 days post-differenti-
ation, adipocytes were trypsinized (5 trypsin, EDTA) (Life
Technologies, Inc.) at 37 °C, washed twice with PBS, and
resuspended in electroporation solution (20 mM HEPES, 135
mM KCl, 2 mM MgCl2, 0.5% Ficoll 400, 1% DMSO, 2 mM ATP,
and 5 mM glutathione, pH 7.6) with 200 nM scrambled (sense
5-CAGTCGCGTTTGCGACTGGTT-3) or pooled anti-
TUSC5 siRNA (sense 5-GGAGAACAAGGAUGACCAATT-
3, 5-GGGCAUCGUUAUCAUCAUUTT-3, 5-UCCUCCG-
UCAUCACCACAUTT-3). (Shanghai Genepharma). Cells
were electroporated at 200 mV for 20 ms using an ECM 830
square wave electroporation system (BTX Molecular Delivery
Systems) and seeded onto Matrigel (Corning)-coated
coverslips or plates. Cells were assayed 96 h following
electroporation.
Cell Lysis—3T3-L1 adipocytes were serum-starved in basal
DMEM for 2 h before incubation with 0.5 or 100 nM insulin for
20 min where indicated. Cells were washed twice with PBS and
lysed 1% SDS in PBS-containing protease inhibitors (Roche
Applied Science), 1 mM sodium pyrophosphate, 2 mM sodium
orthovanadate, 10 mM sodium fluoride. Cell lysates were soni-
cated for 12 s and centrifuged at 13,000  g. The protein con-
centration of the supernatant was determined by BCA assay
(Thermo Scientific).
SDS-PAGE and Western Blotting—10 g of protein were
resolved by SDS-PAGE and transferred to PVDF membranes.
Membranes were blocked in 5% BSA or skim milk powder in
TBS-T (0.1% v/v Tween 20 in Tris-buffered saline) for 1 h fol-
lowed by an overnight incubation at 4 °C with specific primary
antibody solutions. Membranes were incubated with an appro-
priate secondary antibody for 1 h before signals were detected
using ECL (Thermo Scientific or Millipore) on the Chemidoc
MP (Bio-Rad). Data analysis was performed using ImageJ or
Image Lab version 5.2.1 (Bio-Rab). Antibodies detecting AKT,
Ser(P)-473 AKT, Thr(P)-308 AKT, TBC1D4, Thr(P)-642
TBC1D4, and Tyr(P)-100 were obtained from Cell Signaling
Technology. IRS-1, IR, TUSC5, and 14-3-3 were detected
using antibodies obtained from Santa Cruz Biotechnology.
Antibodies against IRAP and GLUT4 were generated in-house.
Densitometry analysis was performed using Image Lab 5.2.1
(Bio-Rad). For determination of TUSC5 level, all molecular
weight bands present were included for quantification.
qPCR—Total RNA was extracted from cells using TRIzol re-
agent (Invitrogen). cDNA synthesis was carried out using Pri-
meScript first strand cDNA synthesis kit (Clontech and Takara
Bio Company). PCRs were performed on the LightCycler 480 II
(Roche Applied Science) using FastStart Universal SYBRGreen
Master (Roche Applied Science). Cyclophilin b was used as
an internal control. The primer sets used were as follows:
mTusc5-F, ggtccttgccattgcctctt, and mTusc5-R, tgctgcacactac-
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ttcgagac; mGlut4-F, gacggacactccatctgttg, and mGlut4-R, gcc-
acgatggagacatagc; mCypB-F, and ttcttcataaccacagtcaagacc;
mCypB-R, accttccgtaccacatccat.
2-[3H]Deoxyglucose Uptake Assay—3T3-L1 adipocytes were
serum-starved in basal DMEM for 2 h before being washed
three times in warm PBS and incubated in Krebs-Ringer buffer
(KRP) (0.6 mM Na2HPO4, 0.4 mM NaH2PO4, 120 mM NaCl, 6
mM KCl, 1 mM CaCl2, 1.2 mMMgSO4 and 12.5 mM HEPES, pH
7.4) with 0.2% BSA. Cells were stimulated with 0.5 or 100 nM
insulin for 20min. To determine nonspecific glucose uptake, 25
M cytochalasin B was added to the wells before addition of
2-[3H]deoxyglucose (2DOG). During the final 5 min of insulin
stimulation, 2DOG uptake was initiated by addition of 2DOG
(0.125 Ci/well, 50 M unlabeled 2DOG) (PerkinElmer Life
Sciences). Following three rapid washes in ice-cold PBS, cells
were solubilized in 1% (w/v)TritonX-100 inPBSon a shaker for
1 h and assessed for radioactivity by scintillation counting using
a -scintillation counter. All data were normalized to protein
content.
HA-GLUT4Assay—Measurement of cell surfaceHA-GLUT4as
a percentage of total cellular HA-GLUT4 was performed in
96-well plates as described previously (50). Briefly, cells were
serum-starved for 2 h in basal DMEM. Cells were stimulated
with 0.5 or 100 nM insulin as indicated. Cells were subsequently
fixed but not permeabilized, and the amount of HA-GLUT4
present at the plasma membrane was determined from the
accessibility of the HA epitope to anti-HA antibody (Covance).
Cells were incubated with 20 g/ml goat anti-mouse Alexa-
488-conjugated secondary antibody (Life Technologies, Inc.).
Determination of total HA-GLUT4 level was performed in a
separate set of wells that underwent the same labeling proce-
dure except that anti-HA stainingwas performed after permea-
bilization with 0.1% (w/v) saponin. Total HA-GLUT4 levels
were measured separately for each experimental treatment
group. Fluorescence (excitation 485 nm/emission 520 nm) was
measured using a fluorescent microtiter plate reader (FLUO-
star Galaxy, BMG LABTECH). Surface levels of HA-GLUT4
were expressed as a percentage of total HA-GLUT4.
Results
Proteomic Analysis of GLUT4 Storage Vesicles—To identify
potential regulators of insulin-stimulated GLUT4 trafficking in
adipocytes, we performed proteomic profiling of GSVs. We
immunoisolated GSVs from both unstimulated and insulin-
stimulated primary rat adipocytes using an antibody raised
against the C terminus of GLUT4.We used two differentmem-
brane preparations derived from differential centrifugation as
starting material. One was a mixture of cytosol and small vesic-
ular membranes referred to as pHS. The second was composed
of small vesicular membranes (LDM). Immunoisolated vesicles
were fractionated by SDS-PAGE prior to peptide extraction for
analysis by liquid chromatography-tandem MS (LC-MS/MS).
An advantage of this in-gel approach was that it facilitated par-
tial separation of immunoglobulin heavy and light chains from
GSV proteins. MS analysis identified 1,694 proteins across all
test and control conditions (supplemental Table S1). We iden-
tified 309 and 788 proteins in both replicates of the LDM and
pHS preparations, respectively (Fig. 1A). There was a high
degree of overlap in proteins identified using each of the above
isolationmethods (304/309) (Fig. 1A) so both protein lists were
merged prior to statistical analysis (304 proteins, n 4).
We used the well established GSV proteins GLUT4, IRAP
(51), sortilin (10), and VAMP2 (52) to determine the character-
istics of GSV proteins within our dataset. These proteins had
three distinct features as follows: 1) theywere present in all four
replicates and were significantly enriched in GSVs under
unstimulated conditions using the IgG control immunoisola-
tion as a background value (enrichment) (Fig. 1B); 2) the abun-
dance (LFQ intensity) of these proteins in GSVs from unstimu-
lated adipocytes was above the median for the population
(intensity) (Fig. 1C); and 3) their abundance was significantly
reduced in GSVs isolated from insulin-stimulated adipocytes
(insulin responsiveness) (Fig. 1D).
Using these criteria we identified 69 proteins that were
enriched inGSVs (n 4, integrated p 0.05), 59 of whichwere
above the intensity cutoff (mean log2 intensity21.4933) (Fig.
1, B, red and blue circles, and C, red and blue circles, and sup-
plemental Table S2). This list included proteins that regulate
vesicle trafficking, including RAB proteins (1b, 5b, 11b, and 14),
proteins involved in SNARE complex formation (syntaxins 6, 7,
and 12 and VAMPs 2 and 3), and proteins involved in general
trafficking processes (scamps 1 and 2, VTI1a, VPS26b, and
VPS35) giving a cumulative profile of the GLUT4 trafficking
itinerary. In view of the robustness of this filtering procedure,
certain bona fide GSV proteins, including TBC1D4 (9), RAB10
(9, 16, 53), and LRP1 (16), were not included in this list,
although they were identified in at least one of the four GSV
preparations.
Wemeasured reduced abundance of bona fideGSV residents
in GSVs isolated from insulin-stimulated adipocytes due to the
mobilization of GSVs to the plasma membrane. 23 of the 59
enriched proteins were insulin-responsive (n  4, integrated,
p 0.05, see supplemental Table S3) (Fig. 1D). Notably, despite
significant loss of GLUT4 from the immunoprecipitation start-
ing material due to translocation of GLUT4 to the PM
(observed in Fig. 2,B andC), not all coimmunoisolated proteins
exhibited reduced abundance following insulin stimulation.
The list of 23 insulin-responsive proteins included those previ-
ously found on GSVs such as syntaxin 6 (9, 16), syntaxin 7 (16),
and syntaxin 12 (9, 16), RAB14 (9, 16), VTI1A (16), cystatin-3
(9, 16), and SCAMP2 (9, 16) and SCAMP1 (16) (Fig. 1D).
Validation of TUSC5 as a GSV Protein—Our analysis identi-
fied six novel GSV residents (supplemental Table S3). These
were 2-microglobuli (B2M), 1-antiproteinase (SERPINA1),
coatomer subunit  (COPA), granule cell differentiation pro-
tein/myotrophin (GDP/MTPN), apoptosis-inducing factor 2
(AIFM2), and TUSC5. Tusc5 is a reported PPAR target gene,
and its expression is induced during adipocyte differentiation
(54, 55), suggesting it may have a role in adipocyte function.
Consistent with this, Tusc5 mRNA is enriched in mouse and
human adipose tissue (56). To confirm these findings, we per-
formed immunoblotting with a TUSC5 antibody using a panel
of mouse tissues. The antibody labeled one principal band of
20 kDa (Fig. 2A, *), similar to the predictedmolecular mass of
TUSC5 (18.7 kDa) as well as additional higher molecular mass
bands of around 30 kDa (Fig. 2A, **). A similar molecular mass
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distribution was observed in 3T3-L1 adipocytes (Fig. 4A), and
all bands were sensitive to siRNAs directed to TUSC5. These
immunoreactive bands were only detected in adipose tissues
with no detectable product in other tissues, including muscle
and liver. Intriguingly, the higher molecular mass band was
absent from BAT but abundant in epididymal fat.
TUSC5 levels in the LDM (Fig. 2B) or pHS (Fig. 2C) starting
material was reduced in response to insulin, implying translo-
cation of TUSC5 out of this subcellular compartment with
insulin. TUSC5 was enriched in GSVs isolated from unstimu-
lated adipocytes to a similar extent in both primary adipocytes
and 3T3-L1 adipocytes, and the level of TUSC5 in GSVs was
reduced with insulin stimulation similar to GLUT4 and IRAP.
Notably, the single TUSC5-specific band identified in these
immunoprecipitations was equivalent to the20-kDa band in
Fig. 2A (*).
We further corroborated TUSC5 localization to the GSV
compartment by confocal microscopy in 3T3-L1 adipocytes
(Fig. 2D). We analyzed unstimulated adipocytes because GSVs
are highly insulin-responsive, and the number of GSVs ismark-
edly reduced after stimulation. TUSC5was present at the PM in
unstimulated adipocytes aswell as in the perinuclear region and
in punctate cytosolic structures (Fig. 2D). There was consider-
able heterogeneity in the expression of TUSC5 between indi-
vidual cells. The inter-cell variance in expression ofGLUT4 and
EEA1 was relatively low by comparison (Fig. 2D, top panel).
There was a high level of colocalization between TUSC5 and
GLUT4 in the perinuclear region and in smaller punctate
peripheral structures in adipocytes (Fig. 2D,middle and bottom
panels), but there was limited colocalization between TUSC5
and EEA1 (Fig. 2D, open arrowheads). Indeed, the majority of
structures that were GLUT4- and TUSC5-positive were EEA1-
negative (Fig. 2D,middle and bottompanel, closed arrowheads).
TUSC5 Translocates to the PM in Response to Insulin—
Because TUSC5 is an integral membrane protein localized to
GSVs, we predicted that TUSC5 would undergo insulin-re-
sponsive translocation to the plasmamembrane. In the absence
of insulin, TUSC5 was enriched in the LDM fraction, and this
was reduced by 57% in response to insulin. The reduction in
TUSC5 levels in the LDM was similar to that observed for
GLUT4 (53%) and IRAP (61%). There was a 3.7-fold
increase in TUSC5 at the PM (Fig. 3, A–C) similar to that
observed for other GSV cargo proteins (Fig. 3, A–C).
We detected a single 20-kDa TUSC5 band in the LDM
(Fig. 3A, *), whereas multiple bands were detected in the PM
(Fig. 3A, **). The increase in TUSC5 at the PM was dominated
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by the lower molecular mass of TUSC5 (Fig. 3A, *). The level of
TUSC5 in the PM relative to the LDM in the absence of insulin
was greater for TUSC5 than for either GLUT4 or IRAP (Fig.
3A). This was consistent with the distribution of TUSC5
observed by confocal microscopy (Fig. 2D).
We further interrogated TUSC5 translocation to the PM
TIRF microscopy, which excites fluorophores in close proxim-
ity to the plasma membrane. By staining unpermeabilized adi-
pocytes overexpressing the GLUT4 reporter construct
HA-GLUT4 (50), we were able to specifically label PM TUSC5
and HA-GLUT4 levels in single cells (Fig. 3D).
To examine the change in abundance of HA-GLUT4 and
TUSC5 at the PM in response to insulin, we plotted the distri-
bution of TIRF signal intensities for HA-GLUT4 and TUSC5
from800 cells under basal (black bars) and insulin-stimulated
conditions (gray bars) (Fig. 3, E and F). Insulin stimulation sig-
nificantly increased the number of cells with a higher TIRF
signal intensity for HA-GLUT4. The same effect was observed
for TUSC5. This indicated insulin-stimulated translocation of
these proteins to the PM (Fig. 3, E and F, gray bars).
To further support this observation, we adapted the ap-
proach to quantify endogenous GLUT4 and TUSC5 transloca-
tion in permeabilized cells. This enabled assessment of the
amount of GLUT4 and TUSC5 at the PM relative to their total
expression levels (TIRF/epifluorescence) (Fig. 3G). Consistent
with our other observations, insulin stimulation resulted in a
2.2- and 1.5-fold translocation ofGLUT4 andTUSC5 to the cell
periphery, respectively (Fig. 3H).
These data provide evidence that TUSC5 translocates from
the LDM fraction to the PM in response to insulin. Further-
more, the magnitude of the TUSC5 and GLUT4 responses was
similar, implying that they are delivered to the PM by the same
carriers.
TUSC5 Is a Novel Positive Regulator of Insulin-stimulated
Glucose Transport—Having confirmed TUSC5 localization to
GSVs, we next investigatedwhetherTUSC5plays a role in insu-
lin-regulated glucose transport. Because TUSC5 was similarly
localized to GSVs in both primary and cultured adipocytes, we
performed all subsequent analyses in 3T3-L1 adipocytes as
these cells can be more readily manipulated to alter TUSC5
expression levels. We tested a panel of three siRNAs individu-
ally or in combination to assess their efficacy in reducing
TUSC5 protein expression. All siRNAs reduced Tusc5 expres-
sion levels (Fig. 4A), with siRNA #3 (69%) and the pooled
treatment (71%) having greatest efficacy (Fig. 4B). To assess
the role of TUSC5 in insulin action, we next examined insulin-
dependent 2DOGuptake in siRNA-treated cells treatedwith an
insulin dose equivalent to the ED50 value for glucose transport
(0.5 nM) and a maximal dose (100 nM) to distinguish between
effects on insulin sensitivity and the maximal response to insu-
lin. In cells transfectedwith scrambled siRNA, insulin increased
2DOGuptake by 4.5- and 8.3-fold in response to 0.5 and 100 nM
insulin, respectively (Fig. 4C). Knockdown of TUSC5 resulted
in a significant impairment of insulin-stimulated 2DOG
uptake. The degree of impairment in 2DOG uptake correlated
with the level of knockdown as follows: siRNA #3 and the
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pooled siRNA treatment reduced insulin-stimulated 2DOG
uptake by 50 and 38%, respectively, at 0.5 nM insulin and by 27
and 23%, respectively, at 100 nM insulin. For subsequent exper-
iments, we used the combined siRNA treatment.
To explore this phenotype further, we examined insulin-reg-
ulated GLUT4 traffic (Fig. 4D) (50). In control cells, PM HA-
GLUT4 was increased by 2.0- and 2.7-fold at 0.5 and 100 nM
insulin, respectively. In TUSC5 knockdown cells, insulin-stim-
ulated HA-GLUT4 translocation was significantly blunted at
both 0.5 and 100 nM insulin.
The studies above indicated that loss of TUSC5 impairs insu-
lin action in adipocytes.Wenext determined the effects of over-
expression of TUSC5 on insulin action (Fig. 4E). TUSC5 over-
expression markedly increased 2DOG uptake and HA-GLUT4
translocation at 0.5 nM insulin but not at 100 nM insulin (Fig. 4,
F and G). A more detailed analysis of this effect revealed that
TUSC5 overexpression enhanced insulin sensitivity as mea-
sured by a lowering of the ED50 value for insulin-stimulated
GLUT4 translocation from 0.5 to 0.2 nM (Fig. 4G, inset).
To explore the mechanism for changes in 2DOG uptake in
response to altered TUSC5 expression, we next examined
GLUT4 expression levels in TUSC5 knockdown cells and in
cells overexpressing TUSC5. GLUT4 protein levels were
reduced by 21% in adipocytes treated with TUSC5-directed
siRNA, although IRAP was not affected (Fig. 4, H and I). Glut4
mRNAexpressionwas unaffected in these cells (Fig. 4J). In con-
trast, we did not observe changes in GLUT4 or IRAP protein
levels in response to TUSC5 overexpression (Fig. 4K).
We next examined how TUSC5 knockdown and TUSC5
overexpression affected insulin signaling responses. We moni-
tored insulin signaling at the level of protein phosphorylation of
proximal (insulin receptor, IRS1, and AKT) and more distal
(TBC1D4) signaling elements by Western blotting using phos-
phosite-specific antibodies. Neither knockdown nor overex-
pression of TUSC5 resulted in a change in the total protein
levels of any of the signaling molecules tested (Fig. 4, L andM).
However, TUSC5 knockdown significantly inhibited insu-
lin-stimulated phosphorylation of IRS1, AKT Thr-308, and
TBC1D4 Thr-642 at 0.5 nM and of insulin receptor, IRS1, and
AKTThr-308 at 100 nM insulin (Fig. 4, L andN). In contrast, we
detected no change in insulin signaling in cells overexpressing
TUSC5 (Fig. 4,M andO), despite enhanced insulin sensitivity at
the level of 2DOGuptake andHA-GLUT4 translocation (Fig. 4,
F and G).
Loss of TUSC5 had pleiotropic effects on insulin-regulated
glucose transport, thus inhibitingGLUT4 trafficking to the PM,
reducing GLUT4 expression, and disrupting insulin signaling.
However, the effect of TUSC5 overexpression was confined to
enhancement of 2DOG uptake and GLUT4 translocation.
Taken together, these genetic studies point toward TUSC5
playing a positive role in insulin-stimulated glucose transport at
the level of regulated GLUT4 traffic. Inconsistencies in the
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effects onGLUT4 protein levels and insulin signaling responses
in TUSC5 knockdown and overexpression models suggest that
these factors are not responsible for changes in insulin sensitiv-
ity that occur with altered TUSC5 expression.
TUSC5 Is Required for the Insulin-sensitizing Effects of
Rosiglitazone—Tusc5 expression levels are decreased in epidid-
ymal white adipose tissue of obese rats (56). Furthermore, it has
been reported thatTusc5 expression is regulated by PPAR (54,
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55). PPAR agonists, such as the thiazolidinediones (e.g. rosigli-
tazone), can reverse insulin resistance in adipocytes (20–24).
However the mechanisms by which PPAR activation confers
this benefit are not fully understood (20–32). In light of these
data and our finding that TUSC5 regulates insulin-stimulated
glucose transport in adipocytes (Fig. 4), we hypothesized that
TUSC5 expression may be reduced in insulin resistance and
that PPAR agonists may work in part by restoring TUSC5
expression levels. To study this, we used the TNF model of
insulin resistance in 3T3-L1 adipocytes, which has been
reported to be reversed by treatment with the PPAR agonist
pioglitazone (21). TNF markedly reduced Tusc5 mRNA
(76%) and protein levels (54%), and Tusc5 expression was
rescued at both levels by cotreatment with rosiglitazone (Fig. 5,
A–C).
We assessed whether rescue of TUSC5 expression was suffi-
cient to overcome TNF-induced insulin resistance. Overex-
pression of Tusc5 under the control of an exogenous promoter
rendered Tusc5 mRNA insensitive to TNF (Fig. 5D). We
observed a small TNF-induced reduction in TUSC5 protein
expression (Fig. 5E), but TUSC5 expression was maintained at
levels in untreated control cells (Fig. 5E). Notably, different
molecular weight forms of TUSC5 appeared differentially sen-
sitive to TNF (Fig. 5E). Rescue of TUSC5 expression did not
protect adipocytes from TNF-induced insulin resistance (Fig.
5F), loss of GLUT4 (Fig. 5E), or inhibition of insulin signaling
(Fig. 5G).
We next determined whether TUSC5 was necessary for the
reversal of TNF-induced insulin resistance by the PPAR ago-
nist rosiglitazone. In untreated cells, rosiglitazone did not
enhance insulin-stimulated 2DOG uptake (Fig. 5H) despite
increasing GLUT4 expression (
20%) (Fig. 5, I and J) and insu-
lin signaling (
37%) (Fig. 5, K and L). TNF treatment caused
insulin resistance as indicated by a 44% reduction in insulin-
stimulated 2DOG uptake (Fig. 5H), loss of GLUT4 (48%, Fig.
5I), and reduced insulin-regulated AKT phosphorylation
(54%, Fig. 5K). Rosiglitazone reversed TNF-induced defects
in insulin-stimulated 2DOG uptake in adipocytes that were
transfected with scrambled siRNA (Fig. 5H). Furthermore,
rosiglitazone increased GLUT4 expression by 44% (Fig. 5, I and
J) and insulin-mediated AKT phosphorylation at Thr-308 by
60% (Fig. 5, K and L) in these cells.
These data provided a response profile from which we could
determine whether loss of TUSC5 altered adipocyte responses
to rosiglitazone. In untreated cells, TUSC5 knockdown blocked
GLUT4 expression in response to rosiglitazone (Fig. 5J) but did
not prevent enhanced in signaling to AKT (Fig. 5, K and L). In
contrast, TUSC5 knockdown completely blocked all rosiglita-
zone responses in TNF-treated cells so that no rosiglitazone
responsewasmeasured at the level of insulin-stimulated 2DOG
uptake (Fig. 5H), GLUT4 expression (Fig. 5, I and J), or insulin
signaling (Fig. 5, K and L).
Discussion
We performed proteomic analysis of the GLUT4 storage
compartment to identify novel GSV cargo and regulators of
insulin-stimulated glucose transport. These studies led to the
identification of six proteins not previously reported to be GSV
residents.One of these proteins, TUSC5,was highly enriched in
adipose tissue, underwent insulin-dependent translocation to
the PM-like GLUT4, and was found to be a novel regulator of
insulin-regulated glucose transport. Furthermore, Tusc5 is a
PPAR target gene, and we provide evidence that TUSC5 is
required for PPAR agonism to overcome adipocyte insulin
resistance.
FIGURE 4. TUSC5 is a positive regulator of insulin-stimulatedGLUT4 trafficking.A, total cell lysates from3T3-L1 adipocytes treatedwith scrambled (Scr) or
a panel of three different anti-Tusc5 siRNAs (#1, #2, and #3), or a pool of all three siRNAs (T5) were immunoblotted for TUSC5 to determine the extent of TUSC5
knockdown. B, TUSC5 levels (in A) were quantified by densitometry and expressed as relative to cells treated with scrambled (Scr) siRNA (n 4, mean	 S.E.
one-way ANOVA; **, p 0.01; ***, p 0.001). C, 3T3-L1 adipocytes were treated with scrambled or individual anti-Tusc5 siRNAs (#1, #2, and #3) or a pool of
siRNAs (T5) for 96 h before 2DOG uptake assays were performed at the insulin doses indicated. 2DOG uptake expressed as a percentage of the maximum
response in cells treated with scrambled siRNA (n 4, mean	 S.E., two-way ANOVA; NS, nonsignificant; *, p 0.05; **, p 0.01; ***, p 0.001, comparisons
with control (scr) cells treated with the same insulin dose). D, PM levels of HA-GLUT4 in 3T3-L1 adipocytes overexpressing HA-GLUT4 treated with scrambled
(Scr) or pooled Tusc5 (T5) siRNAwasmeasuredusinga fluorescence-basedassay. Adipocyteswere treatedwith insulin as indicated (n3,mean	S.E., two-way
ANOVA; NS, nonsignificant; *, p  0.05, comparisons with control (scr) cells treated with the same insulin dose). E, retroviral overexpression of TUSC5 was
assessed by immunoblotting whole cell lysates from cells expressing a control vector (empty vector, EV) or overexpressing TUSC5. -Tubulin levels were
determined as a loading control. F, 3T3-L1 adipocytes expressing a control vector (EV) or overexpressing TUSC5 were subjected to 2DOG uptake assays at the
insulin doses indicated. 2DOGuptake expressed as a percentage of themaximum response in cells expressing control vector (EV) (n 4,mean	 S.E., two-way
ANOVA;NS, nonsignificant; **, p 0.01, comparisonswith cells expressing control vector (EV) treatedwith the same insulin dose).G, PM levels of HA-GLUT4 in
3T3-L1 adipocytes overexpressing HA-GLUT4 in combination with a control vector (EV) or TUSC5 were measured using a fluorescence-based assay. PM
HA-GLUT4 levels in adipocyte-treated insulin doses as indicated were plotted as a dose-response curve (n 3, mean	 S.E., two-way ANOVA; NS, nonsignifi-
cant; *,p 0.05; **,p 0.01; ***,p 0.001 comparisonswith cells expressing control vector (EV) treatedwith the same insulin dose). ED50 values for PM-GLUT4
were determined fromnonlinear fitting of dose curves and graphed as an inset (n 3,	 S.E., unpaired t test; *, p 0.05, comparedwith cells expressing empty
vector (EV)). H, GLUT4, IRAP, and 14-3-3 (loading control) levels were assessed by immunoblotting whole cell lysates from control (scr) and TUSC5 knockdown
cells. I, GLUT4 and IRAP levels (H) were quantified by densitometry and are expressed as relative to control (scr) cells (n 3,mean	 S.E., unpaired t test, **, p
0.01, all comparisons with cells treated with scrambled siRNA; dotted line represents levels in cells treated with scrambled siRNA). J, mRNA expression of Glut4
was determined by qPCR in cells treated with scrambled (Scr) and pooled anti-Tusc5 (T5) siRNA. Data were expressed relative to levels in cells treated with
scrambled siRNA (n3,mean	S.E., unpaired t test;NS,nonsignificant, comparedwith cells treatedwith scrambled siRNA).K, levels ofGLUT4, IRAP, and14-3-3
(loadingcontrol)were assessedby immunoblottingwhole cell lysates fromcontrol (EV) cells andcells overexpressingTUSC5. L, insulin signalingwasmonitored
at the level of phosphorylationof insulin receptor (pIR), IRS1 (pIRS1), Thr(P)-308andSer(P)-473AKTandThr(P)-642TBC1D4 in response to0.5 and100nM insulin
in control (scr) cells and cells treated with TUSC5 siRNA. Total levels of insulin receptor (IR), IRS1, AKT, and TBC1D4 were assessed in all conditions, and 14-3-3
was used as loading control.M, insulin signalingwasmonitored at pIR, pIRS, Thr(P)-308 and Ser(P)-473 AKT, and Thr(P)-642 TBC1D4 in response to 0.5 and 100
nM insulin in control (EV) cells and cells overexpressing TUSC5. Total levels of IR, IRS, AKT, and TBC1D4 were assessed in all conditions, and 14-3-3 was used as
loading control. N, quantification of signaling intermediates in L. All data are expressed relative to substrate phosphorylation in response to 100 nM insulin in
control (scr) cells (n 3–5, mean	 S.E., unpaired t test; NS, nonsignificant; *, p 0.05; **, p 0.01, comparisons with cells expressing treated with scrambled
siRNA under the same treatment conditions).O, quantification of signaling intermediates inM. All data are expressed relative to substrate phosphorylation in
response to 100nM insulin in control (EV) cells (n3,mean	 S.E., unpaired t test;NS,nonsignificant, comparisonswith cells expressing treatedwith scrambled
siRNA under the same treatment conditions).
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Our analysis of the GSV proteome yielded 23 proteins that
we have designated as high confidence GSV proteins (supple-
mental Table S3). Although there have been previous pro-
teomic analyses of the adipocyte GSV proteome (9, 16), our
analysis is the first to take into account the “intensity” and
“insulin responsiveness” of proteins to increase confidence of
FIGURE 5. TUSC5 is necessary, but not sufficient, for the insulin-sensitizing effects of rosiglitazone in insulin resistance. A, Tusc5 mRNA levels were
determined by qPCR in cells treated with TNF (2 ng/ml, 96 h) and/or rosiglitazone (10 M, 48 h) as indicated. Data were expressed as relative to Tusc5 levels
in control cells (n  3, mean 	 S.E., unpaired t test; *, p  0.05; ***, p  0.001 for comparisons with untreated cells; ##, p  0.05 for comparisons with
TNF-treated cells). B, TUSC5 levels were determined by immunoblotting in cells treated with TNF (2 ng/ml, 96 h) and/or rosiglitazone (10 M, 48 h) as
indicated. -Tubulin levels were determined as a loading control. C, TUSC5 abundance (B) was quantified by densitometry and expressed as relative to
untreated cells (n 4, mean	 S.E., unpaired t test; *, p 0.05 for comparisons with untreated cells; #, p 0.05 for comparisons with TNF-treated cells). D,
Tusc5 mRNA levels were determined by qPCR in cells expressing an empty vector control (EV) or overexpressing TUSC5 (TUSC5) with and without TNF
treatment. Data were expressed relative to TUSC5 levels in untreated EV adipocytes (n  3, mean 	 S.E., unpaired t test; NS, nonsignificant; *, p  0.05 for
comparisons between untreated and TNF-treated cells as indicated). E, TUSC5, GLUT4, and 14-3-3 (loading control) levels were assessed by immunoblotting
whole cell lysates from cells expressing a control vector (EV) or overexpressing TUSC5 and treated with TNF as indicated (representative of n 4). F, 3T3-L1
adipocytes expressing a control vector (EV) or overexpressing TUSC5 were treated with TNF (2 ng/ml, 96 h) as indicated before 2DOG uptake assays were
performed. 2DOG uptake was expressed as a percentage of the maximum response (n 4, mean	 S.E., two-way ANOVA; NS, nonsignificant; ***, p 0.001;
comparisons with cells expressing control vector (EV) under the same treatment conditions). G, 3T3-L1 adipocytes expressing a control vector (EV) or overex-
pressing TUSC5were treatedwith TNF (2 ng/ml, 96 h) as indicated before insulin signaling at the level of Thr(P)-308 AKTwasmonitored in response to 0.5 or
100 nM insulin (representative of n 4). H, 3T3-L1 adipocytes were treated with scrambled or anti-Tusc5 siRNA for 96 h and treated with TNF (2 ng/ml, 96 h)
and/or rosiglitazone (10M, 48 h) as indicated before 2DOGuptake assays were performed in unstimulated cells or cells stimulatedwith 100 nM insulin. 2DOG
uptake was expressed as a percentage of the maximum response (n 5, mean	 S.E., two-way ANOVA; NS, nonsignificant; *, p 0.05; **, p 0.01; ***, p
0.001, comparisons with control (scr) cells under the same treatment conditions unless otherwise indicated). I, GLUT4, TUSC5, and 14-3-3 (loading control)
levels were assessed by immunoblottingwhole cell lysates from control (scr) and TUSC5 knockdown cells treatedwith TNF and/or rosiglitazone as indicated.
J, quantification of the change in GLUT4 expression in response to rosiglitazone in cells treated with scrambled (Scr) or pooled anti-Tusc5 (T5) siRNA with and
without TNF treatment (n3,mean	 S.E., unpaired t test; *,p0.05, for comparisonswith control (scr) cells under the same treatment conditions).K,3T3-L1
adipocytes were treated with scrambled or anti-Tusc5 siRNA for 96 h and treated with TNF and/or rosiglitazone as indicated before insulin signaling in
response to 100 nM insulin was monitored at the level of Thr(P)-308 AKT (representative of n  3). L, quantification of the change in insulin-stimulated
phosphorylation of AKT at Thr-308 in response to rosiglitazone in cells treated with scrambled (Scr) or pooled anti-Tusc5 (T5) siRNA with and without TNF
treatment (n 3, mean	 S.E., unpaired t test; NS, nonsignificant; *, p 0.05 for comparisons with control (scr) cells under the same treatment conditions).
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hits being part of the GSV compartment. The filtering process
enabled us to identify proteins that exhibit similar features to
bona fideGSV proteins, such as GLUT4, and as such are biased
toward proteins that are enriched in basal GSVs to the exclu-
sion of proteins thatmay, for example, specifically interact with
GSVs following insulin stimulation.
Although the majority of the 23 GSV proteins reported here
have been described previously (supplemental Table S3) (9, 16),
we identified six novel GSV proteins. B2M is a component of
the class I MHC complex (57, 58), and SERPINA1 is a protein-
ase inhibitor (59), and both are secreted proteins. The class I
MHChas been reported to translocate to the PM in response to
insulin in adipocytes, although it did not colocalize with
GLUT4 under basal conditions (60). COPA is a cytosolic pro-
tein involved in the budding of vesicles from the Golgi (61), and
GCDN/MTPNbinds to actin capping protein (62) and has been
reported to be involved in neurotransmitter release in neurons
and glucose-stimulated insulin secretion in beta cells (63, 64).
AIFM2 is a single-pass transmembrane domain protein.
AIFM2 has oxidoreductase activity (65) and has been reported
to be a P53 target gene (66) and mediator of caspase-indepen-
dent apoptosis (67).
TUSC5 is dual-pass membrane protein and was of particular
interest as it was reported to be highly expressed in adipose
depots and to be a target of PPAR, a master regulator of adi-
pocyte function (54–56). It was initially described to be a
deleted gene in lung cancer (68), although there is little known
about its function. It possesses a large extracellular domain that
contains one single N-linked glycosylation site. TUSC5 also
possesses a C-terminal di-Lysmotif. Thesemotifs often encode
binding sites for the coatomer coat complex,which is of interest
because one of the subunits of this complex, COPA, was iden-
tified as a GSV component. Although coatomer is traditionally
thought of as a regulator of endoplasmic reticulum to Golgi
vesicle transport, there is also evidence that it plays a role in
endosomes (69). Hence, it will be of interest to explore the role
of coatomer in GLUT4 trafficking in fat cells.
TUSC5 was validated as a GSV protein in primary and
3T3-L1 adipocytes by immunoprecipitation, andwe observed a
high degree of TUSC5 colocalization with GLUT4 in a nonen-
dosomal compartment (EEA1-negative) in 3T3-L1 adipocytes.
Furthermore, TUSC5 translocated from the LDM fraction to
the PM and also did to a similar extent to GLUT4. These data
further support its localization to the same carrier as GLUT4.
One key difference between the subcellular localization of
TUSC5 and GLUT4 was the relatively large degree of PM
TUSC5 under basal conditions. This raises the question of
where TUSC5 elicits its effect on insulin action. Its colocaliza-
tion with GLUT4 in GSVs and its potential for interacting with
coatomer potentially places its action within the cell. That loss
of TUSC5 resulted in reduced GLUT4 protein levels, indepen-
dent ofGlut4mRNAexpression, and impairedGLUT4 traffick-
ing in TUSC5 knockdown cellsmight indicate a role for TUSC5
in GSV biogenesis. Loss of other integral GSV proteins, IRAP
and LRP1, also result in loss of GLUT4 proteins (16, 70). Alter-
natively, TUSC5 may also play a role at the PM. Intriguingly, a
portion of TUSC5 found on the PM appeared to have a higher
molecular weight than that found in GSVs (Fig. 3A), raising the
possibility that it undergoes post-translational modification
either prior to or in response to movement to the cell surface.
Several pieces of evidence were obtained here to implicate
TUSC5 as a positive regulator of insulin action in adipocytes.
Knockdown of TUSC5 using siRNA resulted in reduced sensi-
tivity to insulin, althoughTUSC5 overexpression had the oppo-
site effect, halving the ED50 value for GLUT4 translocation.
Although knockdown of TUSC5 resulted in a complex array of
additional changes, including reduced GLUT4 expression and
impaired insulin signaling, overexpression did not affect these
parameters. Therefore, we propose that the effect of TUSC5
expression on insulin-regulated GLUT4 traffic is likely not
mediated by changes in GLUT4 expression or signaling. Rather
observed changes in response to TUSC5 knockdown may be
downstream of the defects in GLUT4 trafficking. How TUSC5
acts as an insulin sensitizer is the subject of ongoing work. Our
genetic experiments cannot distinguish between an acute and
chronic role for TUSC5 inmodulating insulin action. However,
the breadth of responses to TUSC5 knockdown (Fig. 4) and
because TUSC5 is required for PPAR-mediated reversal of
insulin resistance (Fig. 5) suggest a longer term role in modu-
lating insulin responses in adipocytes. Of interest, we observed
considerable heterogeneity in TUSC5 expression between indi-
vidual adipocytes (Fig. 2) and as to whether this is linked to the
heterogeneity in insulin action that has been described in
3T3-L1 adipocytes (71) remains to be seen.
PPAR plays an important role as an insulin sensitizer in
adipocytes (17–19), although the exact mechanism by which
this is achieved orwhich PPAR target genes confer this benefit
has not been fully resolved. We have recently shown that insu-
lin resistance in adipocytes is highly selective for GLUT4 traf-
ficking, and so the ability of PPAR agonists to reverse insulin
resistancewould seem to reflect an important role for PPAR in
regulating components of the GLUT4 trafficking process (72).
We have shown that TUSC5 expression was reduced in insulin
resistance, and althoughTUSC5was not sufficient to overcome
insulin resistance, TUSC5 was necessary for the full insulin-
sensitizing effects of rosiglitazone. Our findings that TUSC5 is
highly regulated by PPAR, is expressed at such high levels in
adipose tissue, and that its expression is required for PPAR-
mediated reversal of insulin resistance emphasizes the essential
role of this protein in adipocyte function and in particular the
effects of PPAR agonists in this tissue. Furthermore, it is con-
ceivable that reduced levels of TUSC5 may contribute to the
development of insulin resistance.
However, there are several lines of evidence that suggest that
enhanced TUSC5 expression is not the only effect of PPAR
agonism. First, overexpression of TUSC5 did not recapitulate
the effects of rosiglitazone. Second, TUSC5 expression was not
required for rosiglitazone to enhance insulin signaling in con-
trol cells (Fig. 5, K and L) despite considerable up-regulation of
TUSC5 in response to rosiglitazone (Fig. 5A). It is known that
rosiglitazone can influence signaling via additional mecha-
nisms such as through the induction of a number of signaling
intermediates (23). Therefore, the requirement for TUSC5 for
the insulin-sensitizing effects of rosiglitazone appears to be
context-dependent.
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Overall, we provide evidence that TUSC5 is a novel GSV
protein and regulator of insulin-stimulated glucose transport
responses in adipocytes. TUSC5 is the first PPAR target gene,
other than GLUT4 itself, to provide a direct link between
PPAR activation and the regulation of glucose transport.
Understanding the mechanism by which TUSC5 interacts and
regulates with insulin-regulated GLUT4 traffic may provide
novel insight into this system and the defects associated with
insulin resistance.
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